TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04498026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adherus Dural Sealant System
Description: Adherus Dural Sealant, In situ polymerizing sealant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DuraSeal Exact Dural Sealant System
Description: DuraSeal Exact (P080013b)
Study: NCT04588389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection Location 1
Description: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection Location 2
Description: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Pharmacological Management
Description: standard of care multimodal pharmacological management

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal Pharmacological Management
Description: standard of care multimodal pharmacological management

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal Pharmacological Management
Description: standard of care multimodal pharmacological management
Study: NCT04341324

Intervention type: OTHER
Intervention: It is an observational study.
Study: NCT00626808

Intervention type: DRUG
Intervention: No Intervention
Description: There were no interventions. No subjects were enrolled in this retrospective database study.

Intervention type: DRUG
Intervention: No Intervention
Description: There were no interventions. No subjects were enrolled in this retrospective database study.
Study: NCT03474887

Intervention type: OTHER
Intervention: Physical Consultation
Description: Regular physician consultation at the primary care clinic.
Study: NCT01292005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
Study: NCT02913716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: defactinib
Description: Single oral dose of 400 mg \[14C\]-defactinib
Study: NCT03474887

Intervention type: OTHER
Intervention: Physical Consultation
Description: Regular physician consultation at the primary care clinic.

Intervention type: OTHER
Intervention: Physical Consultation
Description: Regular physician consultation at the primary care clinic.

Intervention type: OTHER
Intervention: Online Consultation
Description: An online platform for communicating with a physician digitally. Patients answer a series of algorithm-based questions after specifying chief complaint, after which contact is established with a physician who can communicate through short messages. The physician can then order labs, prescribe relevant medication or book the patient for a physical consultation if need be.

Intervention type: OTHER
Intervention: Online Consultation
Description: An online platform for communicating with a physician digitally. Patients answer a series of algorithm-based questions after specifying chief complaint, after which contact is established with a physician who can communicate through short messages. The physician can then order labs, prescribe relevant medication or book the patient for a physical consultation if need be.
Study: NCT02123368

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Single intraarticular injection of Hyaluronic acid (Hyal One)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Single intraarticular injection of Hyaluronic acid (Hyal One)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Single intraarticular injection of Hyaluronic acid (Hyal One)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10 million Bone marrow mesenchimal stem cells
Description: 10 million of Bone marrow mesenchimal stem cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 100 million Bone marrow mesenchimal stem cells
Description: 100 million of Bone marrow mesenchimal stem cells
Study: NCT00999518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: 1 mg dose given subcutaneously twice at an 8-week interval.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: 2.5 mg dose given subcutaneously twice at an 8-week interval.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: 10 mg dose given subcutaneously twice at an 8-week interval.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: 20 mg dose given subcutaneously twice at an 8-week interval.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dose given subcutaneously twice at an 8-week interval.
Study: NCT03223259

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Injury Prevention Workshops
Description: Each workshop will last 90 minutes and consist of approximately 20-30 minutes of lecture, 30 minutes of movement, no more than 20 minutes for a pre-test (workshop 1) or post-test (workshop 2), and remaining time for Q\&A.
Study: NCT02728388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid
Description: Drug: Levulan Kerastick~Drug: Topical placebo~Device: Omnilux Revive~Procedure: Photodynamic therapy~Other: Tumor growth rate measurements
Study: NCT02483117

Intervention type: OTHER
Intervention: Adaptation of the CIA
Description: Adaptation of the CIA into Spanish was performed using the backward-forward translation process, which ensures conceptual. Forward translation into Spanish was carried out by two independent native Spanish speaking translators who were fluent in English. Two other independent translators, totally blind to the original version, whose native language was English and who were fluent in Spanish, back-translated the consensus version into English. After reaching consensus on a final translated version, it was sent to the CIA's original author (Dr. Bohn) who gave her approval. We undertook a cognitive debriefing process with a group of 5 ED patients to identify any problems with language. The pre-final version was administered to two small groups, one made up of patients (a sample of 5 respondents) and the other of clinical experts (2 psychiatrists and 2 psychologists who were experts on ED).
Study: NCT04241406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation
Description: Electrodes are placed over the back for a 10 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing current intensity during 30 second and decrease intensity subsequentl

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation
Description: Electrodes are placed over the back for a 10 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing current intensity during 30 second and decrease intensity subsequentl
Study: NCT03752749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prednisolone + Acute Intermittent Hypoxia
Description: Administration of oral prednisolone followed by 15, 60-second bouts of mild hypoxia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Acute Intermittent Hypoxia
Description: Administration of oral matching placebo followed by 15, 60-second bouts of mild hypoxia
Study: NCT04771637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrolyte and quality of recovery of the patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The loading dose with 1.0 μg/kg, maintenance dose with 0.25 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology and quality of recovery of the patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology and quality of recovery of the patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline is used to observe the effect on the electrophysiology and quality of recovery of the patients
Study: NCT00118950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Tablet Metformin 500 mg; Dosage: 1000 mg two times daily. Duration: Four months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repaglinide
Description: Tablet Repaglinide 1 mg; Dosage: 2 mg three times daily. Duration: Four months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-Metformin.
Description: Tablet Placebo (corresponding to 500 mg Metformin). Dosage: 2 tablets two times daily. Duration: Four months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-Repaglinide.
Description: Tablet Placebo (corresponding to 1 mg Repaglinide). Dosage: 2 tablets three times daily. Duration: Four months.

Intervention type: OTHER
Group type: OTHER
Intervention: Diet-only.
Description: Diet-only treatment. Duration: One month.

Intervention type: OTHER
Group type: OTHER
Intervention: Diet-only.
Description: Diet-only treatment. Duration: One month.
Study: NCT01868477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox DFX, DT
Description: provided as dispersible tablets for oral use in 125 and 250, 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin alpha

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox DFX, FCT
Description: provided as film-coated tablet for oral use in 90, 180, 360 mg strengths
Study: NCT01811186

Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone/naloxone
Description: Oxycodone/naloxone titration

Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone/naloxone
Description: Oxycodone/naloxone titration
Study: NCT01092052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-1116354
Description: Oral daily administration for 14 consecutive days followed by 7 days of rest
Study: NCT04486872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells
Description: Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells injection. Within 3 to 5 days after the pretreatment, the subjects received a single A-02 reinfusion, the infusion dose of each group of subjects 1.00 × 10\^6/kg, 3.00 × 10\^6/kg or 5.00 × 10\^6/kg (if applicable), it is recommended to complete the infusion within 30 min after cell recovery.
Study: NCT00264264

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure Device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Compression
Study: NCT03665311

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 25% Albumin fluid
Description: 25% Albumin fluid (100 mL)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% Normal Saline (100 mL)
Study: NCT00856297

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM conjugate vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: MenACWY-CRM conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed comparator

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licensed comparator

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Licensed comparator
Study: NCT03294850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Subjects enrolling in the study who are undergoing bariatric surgery as part of their medical care will be studied

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Subjects enrolling in the study who are undergoing bariatric surgery as part of their medical care will be studied

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HepQuant SHUNT Dual Cholate Liver Diagnostic Kit
Description: For the experimental group, the device will be used to monitor the effect of bariatric surgery on liver function. For the active comparator group, the device will be used for the assessment of baseline liver function.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HepQuant SHUNT Dual Cholate Liver Diagnostic Kit
Description: For the experimental group, the device will be used to monitor the effect of bariatric surgery on liver function. For the active comparator group, the device will be used for the assessment of baseline liver function.
Study: NCT03342118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phloroglucin(Flospan®)
Description: The experimental group was taken with Phloroglucin(Flospan®) before endoscopy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The control group was treated with normal saline before endoscopy
Study: NCT02697435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Centered Care
Description: Patient-centered care will be directed by geriatricians who have been trained to assess and treat 11 conditions that commonly affect chronic low back pain. Treatments may involve behavioral components, physical therapy, or medical treatments such as cortisone shots, depending on the patient's needs.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Imaging-Directed Care
Description: Imaging-Directed Care will allow patients to follow-up their initial imaging with whatever course they (and/or their doctor) chose, should they chose to follow any course at all.
Study: NCT01742806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bio-absorbable felt(NEOVEIL®)
Description: To cover bio-absorbable felt over the lymphadenectomy area (hepatoduodenal ligament, #5 and 12/gastroduodenal artery, #6/ pancreas head /suprapancreatic area, #7,8 and 9)
Study: NCT03433352

Intervention type: DRUG
Intervention: Methimazole Pill
Description: Patients who developed GD received methimazole treatment

Intervention type: DRUG
Intervention: Methimazole Pill
Description: Patients who developed GD received methimazole treatment

Intervention type: DRUG
Intervention: Propylthiouracil Pill
Description: Patients who developed GD received propylthiouracil treatment

Intervention type: DRUG
Intervention: Propylthiouracil Pill
Description: Patients who developed GD received propylthiouracil treatment
Study: NCT01824433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine
Description: venlafaxine 75-225mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: fluoxetine 20-60mg qd
Study: NCT01217372

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lemon supplementation
Description: 60 ml of lemon juice twice daily (an amount expected to provide 6 grams or 92 mEq of citric acid per day)
Study: NCT04230213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06410293
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: SC injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: SC injection
Study: NCT02301624

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Intravenous administration of eculizumab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Intravenous administration of eculizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous administration of matching placebo. Participants received placebo only during the Blind Induction Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous administration of matching placebo. Participants received placebo only during the Blind Induction Phase.
Study: NCT04651608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: manuel acupressure
Description: Acupressure was applied once by the researcher 30 minutes before applying the chemotherapeutic agent with medium or high emetogenicity to the randomized child. 3 fingers were placed on the child's wrist with their fingers and the region (point P6) between the flexor carpi radians and palmaris longus 1 cm below. Acupressure was applied to the wrist of the child by press for 2 minutes. The same procedure was applied to the other wrist. Then, data were recorded in accordance with the data collection procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sea-band acupressure
Description: 30 minutes before applying the chemotherapeutic agent with medium or high emetogenicity to the randomized child, sea-band acupress was applied by the researcher. The P6 point on the wrist was identified and marked with the child's own fingers. A sea band was attached to both wrists of the child by the researcher. The attached sea-band was allowed to remain for 15 minutes and was removed by the researcher at the end of the period. Separate sea-band was attached to each child. Acupress wrist bands, which are produced in separate sizes for adults and children, were used during the application, taking into account the physical development of the child, pediatric for the age range of 5-12, and adult size sea-band for the age of 12. Acupress application with sea-band was done once. Then, data were recorded in accordance with the data collection procedure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: placebo manuel acupressure
Description: Placebo manual acupress was applied in the next protocol for the child who was administered manual acupressure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: placebo sea-band
Description: Placebo sea-band was applied in the next protocol for the child who was administered sea-band acupressure.
Study: NCT03252002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1101042
Description: Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1101042
Description: Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1101042
Description: Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1101042
Description: Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1101042
Description: Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1101042
Description: Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)
Study: NCT03474887

Intervention type: OTHER
Intervention: Online Consultation
Description: An online platform for communicating with a physician digitally. Patients answer a series of algorithm-based questions after specifying chief complaint, after which contact is established with a physician who can communicate through short messages. The physician can then order labs, prescribe relevant medication or book the patient for a physical consultation if need be.
Study: NCT03252002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)